

## References

1. Chesnutt AN, Chesnutt MS, Prendergast NT, Prendergast TJ. Asthma. In: Papadakis MA, McPhee SJ, Rabow MW. eds. *Current Medical Diagnosis and Treatment 2019* New York, NY: McGraw-Hill;. <http://accessmedicine.mhmedical.com/arcadia.idm.oclc.org/content.aspx?bookid=2683&sectionid=225057896>. Accessed November 8, 2018.
2. Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. *Expert Opin Biol Ther*. 2018;18(7):747–754. doi:10.1080/14712598.2018.1492540
3. Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. *J Asthma Allergy*. 2014;7:123–130. doi:10.2147/JAA.S52387
4. Antoniu SA . Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. *Curr Opin Investig Drugs*. 2010; 11 (11); 1286-94
5. Barranco P, Phillips-Angles E, Dominguez-Ortega J, Quirce S. Dupilumab in the management of moderate-to-severe asthma: the data so far. *Ther Clin Risk Manag*. 2017;13:1139–1149; doi:10.2147/TCRM.S125964
6. White M, Crisalida T, Li H, Economides A, Kaliner M. Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma. *Annals of Allergy, Asthma & Immunology*. 2006;96(3):437-444. doi:10.1016/s1081-1206(10)60911-8.
7. Castro M, Corren J, Pavord ID, Maspero J. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *New Engl J Med*. 2018; 378:2486-2496. doi:10.1056/NEJMoa1804092.
8. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. *New England Journal of Medicine*. 2018;378(26):2475-2485. doi:10.1056/nejmoa1804093.
9. Wenzel S, Ford L, Pearlman D, Spector S. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels. *New Engl J Med*. 2013; 368(26):2455-2466. doi:10.1056/NEJMoa1304048.
10. Corren J, Castro M, Jayawardena S, et al. Dupilumab Improves Astham Control and Asthma-Related Quality of Life in Uncontrolled Persistent Asthma Patients Across All Baseline Exacerbation Rates. *CHEST*. 2017; 152:A26. Doi:10.106/j.chest.2017.08.056.
11. Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor  $\alpha$  antagonist. *J Allergy Clin Immunol*. 2012;130(2):516-22.e4.

12. Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. *J Allergy Clin Immunol*. 2018; 142 (1): 171-177.e1
13. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. *The Lancet*. 2007; 370 (9596): 1422-1431